HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMPACT THERAP-B

11.270

-0.450-3.84%

Volume:3.22M

Turnover:36.81M

Market Cap:3.18B

PE:-8.70

High:11.950

Open:11.950

Low:11.120

Close:11.720

52wk High:47.980

52wk Low:10.310

Shares:282.46M

HK Float Shares:282.46M

Volume Ratio:0.47

T/O Rate:1.14%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.295

ROE:--

ROA:-40.35%

PB:3.51

PE(LYR):-8.70

PS:23.03

Loading ...

Overview Company News Filings

IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform

Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate

Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate

THOMSON REUTERS

IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss

Bulletin Express

Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026

THOMSON REUTERS

Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million

IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026

Bulletin Express

Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion

Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million

IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib

IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries

Bulletin Express

Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others

Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal

THOMSON REUTERS

Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand

THOMSON REUTERS

Impact Therapeutics Shareholders Approve Articles of Association Amendments

Impact Therapeutics Nominates Preclinical Candidate for GI Cancers

MT Newswires Live

Impact Therapeutics Names Ceacam5 Dual-payload ADC Imp3201 as Preclinical Candidate

IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress

Impact Therapeutics Says ESMO 2026 Accepts Posters on Senaparib, Imp1734 and Imp1707 Data

IMPACT Therapeutics to Seek Shareholder Nod on New Share Award Scheme and Articles Amendments at 27 July 2026 EGM

Bulletin Express

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/07630/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"07630","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":11.27,"timestamp":1789546124939,"preClose":11.72,"halted":0,"volume":3221400,"delay":0,"changeRate":-0.038395904436860154,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"Closed","change":-0.45,"latestTime":"09-16 16:08:44","open":11.95,"high":11.95,"low":11.12,"amount":36811208,"amplitude":0.070819,"askPrice":11.27,"askSize":5800,"bidPrice":11.23,"bidSize":2000,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":5,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":11.72,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"volumeRatio":0.468058,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"07630\",,,,,undefined,":{"symbol":"07630","floatShares":282461530,"roa":"-40.35%","roe":"--","lyrEps":-1.294715,"volumeRatio":0.468058,"shares":282461530,"dividePrice":0,"high":11.95,"amplitude":0.070819,"preClose":11.72,"low":11.12,"week52Low":10.31,"pbRate":"3.51","psRate":"23.03","week52High":47.98,"institutionHeld":0,"latestPrice":11.27,"committee":-0.487179,"eps":-1.294715,"divideRate":0,"volume":3221400,"delay":0,"ttmEps":-1.052,"open":11.95,"prevYearClose":20.1,"prevWeekClose":12.9,"prevMonthClose":14.46,"prevQuarterClose":36.08,"fiveDayClose":12.54,"twentyDayClose":11.99,"sixtyDayClose":36.24},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/07630\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"07630","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"07630\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"07630\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":1,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":1,"analysts":1,"updateTime":1782230400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/07630\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"07630","date":"2026-09-15","current":-10.712928,"percent":0.686047,"low":-34.323153,"twenty":-30.011097,"median":-14.055938,"eighty":-10.530318,"high":-8.821219,"avg":-18.930138,"sd":9.299977,"marketCap":3310449131},"quantilePoints":[{"date":"2026-05-15","current":-32.36994,"twenty":-32.973318,"median":-32.357426,"eighty":-26.127101,"marketCap":11057651805},{"date":"2026-05-22","current":-30.548005,"twenty":-32.354923,"median":-30.958502,"eighty":-28.393426,"marketCap":10411425401},{"date":"2026-05-29","current":-32.218614,"twenty":-32.294393,"median":-30.958502,"eighty":-30.148817,"marketCap":11018988687},{"date":"2026-06-05","current":-29.849738,"twenty":-32.359929,"median":-31.257987,"eighty":-30.148817,"marketCap":10223633112},{"date":"2026-06-12","current":-29.369689,"twenty":-32.33377,"median":-30.548005,"eighty":-29.705347,"marketCap":10052410732},{"date":"2026-06-18","current":-29.78235,"twenty":-32.303072,"median":-30.338658,"eighty":-29.742668,"marketCap":10218109810},{"date":"2026-06-26","current":-29.297581,"twenty":-32.241427,"median":-30.11999,"eighty":-29.607619,"marketCap":10002701008},{"date":"2026-07-03","current":-16.26247,"twenty":-32.218614,"median":-29.994357,"eighty":-29.297581,"marketCap":5556442415},{"date":"2026-07-10","current":-15.780707,"twenty":-31.493905,"median":-29.916258,"eighty":-25.475578,"marketCap":5385220035},{"date":"2026-07-17","current":-11.297625,"twenty":-31.022068,"median":-29.816044,"eighty":-15.922995,"marketCap":3869073471},{"date":"2026-07-24","current":-9.271485,"twenty":-30.958502,"median":-29.609087,"eighty":-15.602668,"marketCap":3175898995},{"date":"2026-07-31","current":-10.646015,"twenty":-30.630104,"median":-29.369689,"eighty":-13.307417,"marketCap":3653664669},{"date":"2026-08-07","current":-10.047131,"twenty":-30.493855,"median":-29.24895,"eighty":-10.58915,"marketCap":3454825776},{"date":"2026-08-14","current":-10.299125,"twenty":-30.36699,"median":-25.475578,"eighty":-10.316459,"marketCap":3545960269},{"date":"2026-08-21","current":-10.772628,"twenty":-30.33128,"median":-16.418396,"eighty":-10.292557,"marketCap":3717182649},{"date":"2026-08-28","current":-12.490535,"twenty":-30.224959,"median":-15.896725,"eighty":-10.316459,"marketCap":4310937679},{"date":"2026-09-04","current":-14.62831,"twenty":-30.072679,"median":-15.691688,"eighty":-10.353511,"marketCap":4403575252},{"date":"2026-09-11","current":-12.087934,"twenty":-30.026033,"median":-14.57977,"eighty":-10.495083,"marketCap":3643753737},{"date":"2026-09-15","current":-10.984002,"twenty":-30.011097,"median":-14.055938,"eighty":-10.530318,"marketCap":3310449131}],"updateTime":1789548062589},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"07630\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1133174395","title":"IMPACT THERAP-B Designates IMP2794 as Preclinical Candidate, a Highly Selective KAT6A PROTAC from Its Proprietary Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=1133174395","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133174395?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:20","pubTimestamp":1786526417,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that it has designated IMP2794 as a preclinical candidate compound (PCC), a KAT6A-specific degrader PROTAC discovered through its proprietary targeted protein...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658197808","title":"Impact Therapeutics Names Imp2794 KAT6A Protac Degrader as Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658197808","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658197808?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526190,"startTime":"0","endTime":"0","summary":"Impact Therapeutics names IMP2794 KAT6A PROTAC degrader as preclinical candidateImpact Therapeutics nominated IMP2794 as a preclinical candidate, its first from a proprietary targeted protein degradat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nNDL41R3kz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658978702","title":"Impact Therapeutics - Announces Imp2794 as Kat6a-Specific Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658978702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658978702?lang=en_us&edition=fundamental","pubTime":"2026-08-12 17:16","pubTimestamp":1786526175,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nFWN4490I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128234712","title":"IMPACT Therapeutics forecasts 276%–359% revenue surge and narrower interim loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1128234712","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128234712?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:47","pubTimestamp":1786438029,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. issued a profit alert for the six months ended 30 June 2026, projecting a sharp top-line expansion and a materially reduced loss versus the prior-year period. Revenue is...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658899329","title":"Impact Therapeutics - Expects Revenue of Rmb94.7 Mln-Rmb115.7 Mln for Six Months Ended June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2658899329","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658899329?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437675,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4480E3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658937129","title":"Impact Therapeutics Expects H1 Loss to Narrow to RMB 81.7 Million-RMB 99.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658937129","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658937129?lang=en_us&edition=fundamental","pubTime":"2026-08-11 16:41","pubTimestamp":1786437668,"startTime":"0","endTime":"0","summary":"Impact Therapeutics expects H1 loss to narrow to RMB 81.7 million-RMB 99.9 millionImpact Therapeutics guided for revenue of RMB 94.7-115.7 million for the six months ended June 30, 2026, up 276%-359%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDLbw6wN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103430874","title":"IMPACT Therapeutics Maintains 282.46 Million Issued H Shares and Confirms Public Float Compliance for July 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1103430874","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103430874?lang=en_us&edition=fundamental","pubTime":"2026-08-05 17:28","pubTimestamp":1785922107,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (H shares) filed its Monthly Return for the period ended 31 July 2026, confirming that the company’s equity structure remained unchanged during the month. • Authorised and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147623174","title":"Hong Kong Stock Moves | <b>IMPACT THERAP-B</b> (07630) Plunges Over 13% in Afternoon Trade, Down Nearly 70% Since Early July, Total Market Cap Falls Below HK$3.5 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1147623174","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147623174?lang=en_us&edition=fundamental","pubTime":"2026-08-03 14:12","pubTimestamp":1785737537,"startTime":"0","endTime":"0","summary":"According to financial information, IMPACT THERAP-B (07630) fell over 13% in the afternoon session. As of the time of writing, it was down 12.47% to HK$11.58, with a turnover of HK$5.2774 million. On...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VXUS","BK4585","KCAI","07630","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656328122","title":"Impact Therapeutics Licenses Senaparib Rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2656328122","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656328122?lang=en_us&edition=fundamental","pubTime":"2026-08-03 13:58","pubTimestamp":1785736690,"startTime":"0","endTime":"0","summary":"Impact Therapeutics licenses senaparib rights to Pharmanovia in Europe, Mideast, North Africa, Australia, New Zealand for up to EUR 423.5 millionImpact Therapeutics signed an exclusive license deal wi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDLpsGXW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140891841","title":"IMPACT THERAP-B Surges Over 11% in Early Trading Following Exclusive Licensing Deal for Cancer Drug Senaparib","url":"https://stock-news.laohu8.com/highlight/detail?id=1140891841","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140891841?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:54","pubTimestamp":1785462854,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) saw its share price climb more than 11% in early trading, reaching a high of HK$12.79, representing an 11.02% gain, with trading volume reaching HK$996,900.On July 30, the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107391797","title":"IMPACT Therapeutics, Inc. Secures EUR423.50 Million Licensing Deal With Pharmanovia for Senaparib Across 66 Countries","url":"https://stock-news.laohu8.com/highlight/detail?id=1107391797","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107391797?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:24","pubTimestamp":1785407093,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has entered into an exclusive agreement with global specialty pharmaceutical company Pharmanovia to manufacture, develop and commercialise the PARP1/2 inhibitor senaparib in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878714","title":"Impact Therapeutics Signs Exclusive License Deal with Pharmanovia for Senaparib in Europe, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878714","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878714?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:21","pubTimestamp":1785406891,"startTime":"0","endTime":"0","summary":"BRIEF-IMPACT Therapeutics Signs Exclusive License Deal With Pharmanovia For Senaparib In Europe, OthersJuly 30 (Reuters)-IMPACT Therapeutics Inc7630.HK:EXCLUSIVE LICENSE AGREEMENT WITH PHARMANOVIA FOR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655878268","title":"Impact Therapeutics - Eligible for up to EUR 423.50 Mln Plus Tiered Royalties in Pharmanovia Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2655878268","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655878268?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:18","pubTimestamp":1785406701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1S7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655782548","title":"Impact Therapeutics - Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand","url":"https://stock-news.laohu8.com/highlight/detail?id=2655782548","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655782548?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:17","pubTimestamp":1785406678,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nFWN43W1KI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654011467","title":"Impact Therapeutics Shareholders Approve Articles of Association Amendments","url":"https://stock-news.laohu8.com/highlight/detail?id=2654011467","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654011467?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:48","pubTimestamp":1785149311,"startTime":"0","endTime":"0","summary":"Impact Therapeutics shareholders approve articles of association amendmentsImpact Therapeutics shareholders adopted amendments to the articles of association at a July 27, 2026 extraordinary general m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8Rp10R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654092639","title":"Impact Therapeutics Nominates Preclinical Candidate for GI Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2654092639","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654092639?lang=en_us&edition=fundamental","pubTime":"2026-07-27 14:28","pubTimestamp":1785133700,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  nominated IMP3201, a CEACAM5-targeted dual-payload antibody-drug conjugate , as a preclinical candidate.IMP3201 is the first preclinical candidate developed using its proprietary dual-payload ADC platform, according to a Monday Hong Kong bourse filing. It is being developed to treat gastrointestinal cancers, including colorectal, pancreatic, gastric and esophageal squamous cell carcinoma.Shares of the company fell over 6% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK7095","BK4539","BK1161","NETL","07630","BK4231","ADC","BK4080","BK4139","ADC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654606032","title":"Impact Therapeutics Names Ceacam5 Dual-payload ADC Imp3201 as Preclinical Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2654606032","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654606032?lang=en_us&edition=fundamental","pubTime":"2026-07-27 07:30","pubTimestamp":1785108648,"startTime":"0","endTime":"0","summary":"Impact Therapeutics names CEACAM5 dual-payload ADC IMP3201 as preclinical candidateImpact Therapeutics nominated IMP3201 as a preclinical candidate, a CEACAM5-targeted dual-payload antibody-drug conju","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260726:nNDL1wq6CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116790823","title":"IMPACT THERAP-B: Multiple Research Abstract Summaries Accepted for Poster Presentation at 2026 European Society for Medical Oncology Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1116790823","media":"Stock News","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116790823?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:40","pubTimestamp":1784504433,"startTime":"0","endTime":"0","summary":"The latest clinical data from three key pipeline projects (namely senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004)) have been accepted for poster presentation...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652198268","title":"Impact Therapeutics Says ESMO 2026 Accepts Posters on Senaparib, Imp1734 and Imp1707 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2652198268","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652198268?lang=en_us&edition=fundamental","pubTime":"2026-07-20 07:30","pubTimestamp":1784503848,"startTime":"0","endTime":"0","summary":"Impact Therapeutics says ESMO 2026 accepts posters on senaparib, IMP1734 and IMP1707 dataImpact Therapeutics disclosed multiple oncology study abstracts accepted for poster presentation at the 2026 ES","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260719:nNDL1trcy6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131853640","title":"IMPACT Therapeutics to Seek Shareholder Nod on New Share Award Scheme and Articles Amendments at 27 July 2026 EGM","url":"https://stock-news.laohu8.com/highlight/detail?id=1131853640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131853640?lang=en_us&edition=fundamental","pubTime":"2026-07-10 21:46","pubTimestamp":1783691181,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. has scheduled its first extraordinary general meeting (EGM) of 2026 for 10:00 a.m. on 27 July 2026 at the company’s Board Room, 27F, New Bund Times Square, 399 West Haiyang...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":86,"code":"91000000","status":"200"}]}}